Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

BACKGROUND: Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Pavinder, Feldhahn, Niklas, Zhang, Bin, Trageser, Daniel, Müschen, Markus, Pertz, Veerle, Groffen, John, Heisterkamp, Nora
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2169263/
https://www.ncbi.nlm.nih.gov/pubmed/17958915
http://dx.doi.org/10.1186/1476-4598-6-67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2169263/
https://www.ncbi.nlm.nih.gov/pubmed/17958915
http://dx.doi.org/10.1186/1476-4598-6-67

Ejemplares similares